1. ¹Institute of Pathology, Charité – Universitätsmedizin, Berlin, Germany
2. ²Therapeutic Area Oncology, Nycomed GmbH, Konstanz, Germany
3. ³Department of Urology, Charité – Universitätsmedizin, Berlin, Germany
4. ⁴Institute of Surgical Pathology – University Hospital Zurich, Zurich, Switzerland

Correspondence: Professor Dr G Kristiansen, Institute of Surgical Pathology, University Hospital Zurich (USZ), Schmelzbergstr. 12, Zurich 8091, Switzerland. E-mail: glen.kristiansen@usz.ch

Received 16 October 2007; Revised 18 December 2007; Accepted 19 December 2007; Published online 22 January 2008.

Abstract

High activity of histone deacetylases (HDACs) causes epigenetic alterations associated with malignant cell behaviour. Consequently, HDAC inhibitors have entered late-phase clinical trials as new antineoplastic drugs. However, little is known about expression and function of specific HDAC isoforms in human tumours including prostate cancer. We investigated the expression of class I HDACs in 192 prostate carcinomas by immunohistochemistry and correlated our findings to clinicopathological parameters including follow-up data. Class I HDAC isoforms were strongly expressed in the majority of the cases (HDAC1: 69.8%, HDAC2: 74%, HDAC3: 94.8%). High rates of HDAC1 and HDAC2 expression were significantly associated with tumour dedifferentiation. Strong expression of all HDACs was accompanied by enhanced tumour cell proliferation. In addition, HDAC2 was an independent prognostic marker in our prostate cancer cohort. In conclusion, we showed that the known effects of HDACs on differentiation and proliferation of cancer cells observed in vitro can also be confirmed in vivo. The class I HDAC isoforms 1, 2 and 3 are differentially expressed in prostate cancer, which might be important for upcoming studies on HDAC inhibitors in this tumour entity. Also, the highly significant prognostic value of HDAC2 clearly deserves further study.